Two Studies Show Potential for Novel Biomarkers to Replace Surgical Biopsy in Detecting and Monitoring Lupus Kidney Disease

Lupus Research Institute-Funded Scientists Show Positive Results With Non-invasive Alternatives

NEW YORK, NY – September 29, 2011 – Studies funded by the Lupus Research Institute (LRI) show the potential for two novel and non-invasive tests using biomarkers to assess kidney disease in lupus without the need for biopsy, an invasive procedure. Measurable substances that increase or decrease according to the degree of disease, biomarkers are looked at more and more in diagnosis and treatment.

Results just published in the October 1 issue of Kidney International show that a novel investigational contrast agent developed by Dr. Joshua Thurman at University of Colorado, when used with magnetic resonance imaging (MRI), can detect proteins in the kidney that indicate disease. Similarly, research by Chaim Putterman, MD at Albert Einstein College of Medicine in New York and Chandra Mohan, MD at University of Texas Southwestern Medical Center in Dallas shows potential for a non-invasive test to monitor kidney disease by measuring levels of specific proteins in urine. Both studies, performed in mice, are now moving to investigations in the human disease.